Navigation Links
ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC
Date:7/29/2014

BEVERLY HILLS, Calif., July 29, 2014 /PRNewswire/ -- ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders.  As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.

"We are excited to move ImmunoClin's head office to Washington, D.C.  The location is attractive for obvious regulatory and business reasons, as we continue to progress our strategic growth plan.  Further, under the oversight of officer and director, Chad Johnson, the Washington office will work seamlessly with our established European headquarters in London, United Kingdom and laboratories in central Paris, France," said Dr. Dorothy Bray, Director, President and CEO of ImmunoClin Corporation.

"Washington, D.C. is a great location for the Company's principal office.  ImmunoClin will join the ranks of the expansive tech and healthcare presence in the D.C. area and be positioned to take advantage of the proximity to and interaction with the federal government, including departments and agencies such as HHS, FDA, NIH, USPHS, and USPTO -- not to mention the impressive public and private educational and research institutions located in greater D.C.," said Chad S. Johnson, Esq., Director, COO and General Counsel.  "I am honored to spearhead the efforts of IMCL from our new D.C. office in conjunction with our international board of directors and scientific advisory board."

About ImmunoClin Corporation

ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France -- and principal corporate office being established in Washington, D.C., USA. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.  ImmunoClin holds multiple patents and trademarks on a global basis.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.

ImmunoClin Corporation
Dr. Dorothy Bray, Director, President & CEO
www.immunoclin.com
dorothy.bray@immunoclin.com
Tel: 1.888.267.1175

Investment Inquiries
J. Scott Munro, CFO
scott.munro@immunoclin.com 
Cell: +1 778-987-4308


'/>"/>
SOURCE ImmunoClin Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation Reports Second Quarter 2014 Financial Results
2. China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy
3. United Therapeutics Corporation To Announce Second Quarter 2014 Financial Results Before Market Open On Tuesday, July 29, 2014
4. Collaboration Between Shimadzu Corporation and the MacCoss Lab of Biological Mass Spectrometry, University of Washington
5. A Unique Collaboration of Life Science Leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, has formed Triphase Accelerator Corporation to be an Oncology Development Accele
6. ETEX Corporation announces appointment of Stephen R. La Neve as President and Chief Executive Officer
7. Patient Safety Technologies, Inc. Announces Definitive Agreement to be Acquired by Stryker Corporation for a Purchase Price of $2.22 Per Common Share in Cash
8. Sigma-Aldrich Corporation To Present At 32nd Annual J.P. Morgan Healthcare Conference
9. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
10. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced today that Scandinavian ... training plan management for consistent implementation of standards and regulatory requirements across SHL ... to help improve and streamline their training and employee development programs, which are ...
(Date:3/28/2017)... Philadelphia, PA (PRWEB) , ... March 28, 2017 ... ... Johnston, spoke at a Marketing Roundtable on March 22 in Philadelphia. The event ... WHYY. , The Marketing Roundtable featured breakout groups and interaction ...
(Date:3/28/2017)... March 28, 2017 Summary This ... Enzo Biochem and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/28/2017)... March 28, 2017  The National Pharmaceutical Council (NPC) ... health policy research organization as its newest member. ... Affairs ( North America ), will serve ... "We,re pleased to have Ipsen and Dr. ... Dan Leonard . "We welcome their insights in helping ...
Breaking Biology Technology:
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial ... ...
Breaking Biology News(10 mins):